Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03625349 · ClinicalTrials.gov registry record
Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation
A clinical trial of Aging and Cardiovascular Disease, sponsored by VA Office of Research and Development.
- Active
- Registry status
- 130
- Enrollment target
- 1
- Study location
NCT03625349: Active study of Aging and Cardiovascular Disease, sponsored by VA Office of Research and Development.
NCT03625349 is a study of Aging and Cardiovascular Disease that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 130 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03625349, a study of Aging and Cardiovascular Disease, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
Brief Summary: Current U.S. Veteran demographics reveal an aging population with significant cardiovascular dysfunction. This ultimately manifests as mobility limitation, inactivity, and a subsequent worsening of cardiovascular disease (CVD) that often leads to death. However, despite this clear negative cycle of events, there is not a single clinically accepted, and therefore routinely utilized, method of assessing vascular health. As nitric oxide (NO) is anti-atherogenic and cardioprotective, identifying an in vivo bioassay of NO bioavailability has significant worth in this arena. Fueled predominantly by the VA Merit Award prior to this renewal application, single passive leg movement (sPLM) and the subsequent blood flow increase, measured non-invasively by ultrasound Doppler in the common femoral artery, is emerging as a method by which vascular endothelial function and therefore NO bioavailability can be determined. However, although this work has yielded an initial characterization of sPLM and established this method to be a novel, valid, and a clinically relevant approach to determine vascular health, further understanding of the sPLM response with advancing age and, ultimately, its implementation and assessment in both rehabilitation and clinical arenas is still necessary. With the growing interest in personalized medicine, the development of tools, such as sPLM, that allow individualized assessments to guide the physician, the patient, and the rehabilitative team, are essential. Therefore, two specific aims are proposed that will address the Central Hypothesis that the sPLM paradigm provides a clinically meaningful assessment of endothelial function. First, cardiac rehabilitation will be assessed by sPLM in the elderly, and, coupled with studies in the young, will elucidate the predominant pathways responsible for the change in endothelial function with aging and rehabilitation. Second, the CVD diagnostic value of the sPLM assessment of endothelial functio
Primary Outcome
Doppler ultrasound will be used to assess movement induced hyperemia in the femoral artery.
Conditions Studied
Interventions
- DRUG NG-Monomethyl-L-Arginine
Study Locations (1)
Utah
- VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2027-10-29 |
What the registry record for NCT03625349 still lists
NCT03625349 is an observational study that tracks outcomes without assigning an intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Aging appearing as the primary indexed condition, and to 1 intervention - of which NG-Monomethyl-L-Arginine is the first listed.
NCT03625349 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT03625349 about?
NCT03625349 is a clinical study titled "Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation". Brief Summary: Current U.S. Veteran demographics reveal an aging population with significant cardiovascular dysfunction. This ultimately manifests as mobility limitation, inactivity, and a subsequent worsening of cardiovascular disease (CVD) that often leads to death. However, despite this clear ne...
What is the current status of trial NCT03625349?
This trial is currently active not recruiting. The enrollment target is 130 participants. The study started on 2015-09-01. Estimated completion is 2027-10-29.
What conditions does trial NCT03625349 study?
This clinical trial studies the following conditions: Aging, Cardiovascular Disease.
What interventions are being tested in trial NCT03625349?
The interventions under investigation include: NG-Monomethyl-L-Arginine (DRUG).
Who is sponsoring clinical trial NCT03625349?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03625349 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03625349's enrollment target sits among peer trials
130 67th of 262 higher than 196 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
RECRUITING · Phase 4
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
Using Nicotine to Reverse Age-related Auditory Processing Deficits
RECRUITING · NA
-
Heterogeneity of Vascular Adaptations to Exercise With Aging in Women and Men
RECRUITING · NA
-
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI